Definium Therapeutics Rebrands and Highlights 2026 Pipeline
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mind Medicine ( (MNMD) ) just unveiled an announcement.
On January 9, 2026, the company formally changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc., a rebranding approved by the board the same day and publicly announced on January 12, 2026, with its shares set to begin trading under the new Nasdaq ticker symbol DFTX on January 13, 2026 without requiring any action from shareholders or changes to its CUSIP. The rebrand underscores Definium’s evolution into a late-stage psychiatry-focused developer, highlighting a 2026-heavy clinical and corporate catalyst calendar that includes four Phase 3 trials of lead candidate DT120 ODT in generalized anxiety disorder and major depressive disorder, expected Phase 3 readouts across these indications, advancing commercial readiness for a potential DT120 launch, and progress in its early-stage pipeline with DT402 in autism spectrum disorder, moves that could solidify its position in the competitive psychiatric therapeutics market and heighten investor focus on upcoming clinical milestones.
The most recent analyst rating on (MNMD) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Mind Medicine stock, see the MNMD Stock Forecast page.
Spark’s Take on MNMD Stock
According to Spark, TipRanks’ AI Analyst, MNMD is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing losses and cash burn), partially offset by a strengthened funding position and positive trial/guidance updates. Technically the trend is supportive with strong moving-average alignment and positive momentum, while valuation remains unattractive/less informative due to losses and no dividend.
To see Spark’s full report on MNMD stock, click here.
More about Mind Medicine
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is a New York–based biopharmaceutical company focused on developing next-generation, psychedelic-inspired therapeutics targeting the underlying causes of psychiatric and neurological disorders. The company is positioning itself as a leader in late-stage psychiatric drug development, with a pipeline led by DT120, an orally disintegrating tablet that has received FDA Breakthrough Therapy Designation for generalized anxiety disorder, alongside early-stage programs such as DT402 for autism spectrum disorder; its shares trade on Nasdaq under the ticker symbol DFTX as of January 13, 2026.
Average Trading Volume: 2,008,071
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.45B
See more data about MNMD stock on TipRanks’ Stock Analysis page.
